Log in to save to my catalogue

Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 I...

Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 I...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1923263575

Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study

About this item

Full title

Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study

Publisher

United States: Oxford University Press

Journal title

Clinical infectious diseases, 2017-07, Vol.65 (1), p.13-19

Language

English

Formats

Publication information

Publisher

United States: Oxford University Press

More information

Scope and Contents

Contents

Background. Patients chronically infected with genotype 3 hepatitis C virus (HCV) have faster disease progression and are less responsive to current direct-acting antiviral regimens than patients infected with other genotypes. We conducted an open-label trial to evaluate the safety, tolerability, and efficacy of ledipasvir and sofosbuvir plus ribav...

Alternative Titles

Full title

Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_1923263575

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1923263575

Other Identifiers

ISSN

1058-4838

E-ISSN

1537-6591

DOI

10.1093/cid/cix289

How to access this item